Novo Nordisk shares tumbled as much as 7.7% in Copenhagen trading after Wall Street analysts questioned the Danish drugmaker's turnaround efforts amid the loss of its GLP-1 lead to Eli Lilly & Co.
At its capital markets day earlier in London, Novo outlined plans for more than five blockbuster launches and over $23 billion in new sales in the coming years. But that comes as its obesity-market lead has been surrendered to Eli Lilly, and analysts were hoping for more commentary from management about turnaround efforts as the stock is down 18% on the year.
"Investors are selling the shares because they are not seeing concrete news that could drive the stock higher," Nordnet investment economist Per Hansen wrote.
CEO Mike Doustdar told analysts, "We need to work harder, and we will." However, much of the optimism from capital markets a few years ago about Novo leading the GLP-1 race has all but faded.
Much of Novo's medium-term outlook rests on CagriSema, according to Bloomberg Intelligence analysts Michael Shah and Christos Nikoletopoulos. That treatment has already disappointed Wall Street multiple times, including failing to match Lilly's Zepbound in a head-to-head trial. Other potential growth drivers remain earlier in development and carry a higher risk of failure
From the peak of the GLP-1 craze in mid-2024, Novo shares in Copenhagen have plunged a staggering 74%, with shares stabilizing since August 2025.
"The event came amid mounting investor pressure for clarity beyond obesity drugs Wegovy and Ozempic as Novo's semaglutide patent expiries approach in the early 2030s. Investors were increasingly focused on Novo’s next growth drivers following setbacks for obesity candidate CagriSema. Novo said it expects revenue growth between 2026 and 2030 to be in line with industry peers," UBS analyst Nana Antiedu wrote in a note.
Novo has been pursuing a turnaround effort this year, already leading to substantial restructuring. Doustdar has cut as many as 9,000 jobs and removed several management layers, with total cuts reaching about 13,000. Novo is also pursuing new therapeutic areas and using AI to accelerate drug development.